Sarepta cuts its operating loss to $9m, but can new RNA drugs offset Elevidys’ decline?
Sarepta narrows its Q3 operating loss to $9 million as Elevidys sales fall 37%. Examine safety, RNA pipeline data and guidance.
Pharma & Biotech